Nkarta will let go about 10% of its workforce as it focuses on applying off-the-shelf cell therapy to an autoimmune disease, it disclosed in an SEC filing Tuesday morning.
The reduction of 18 positions will occur by the end of this year and is expected…
Click here to view original post
